-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Toward More Inclusive, Accessible Clinical Trial Consent Forms
It is a trend many years in the making, but the time is ripe to fix the increasing problems with clinical trial consent documentation. The word count and complexity of mandated information in informed consent forms have been multiplying, but their value remains dubious. In 2016, Danish researchers studying consent forms found that “a considerable…
-
Bronchoscopic Ablation: A Small Step for Heat Therapy, a Giant Leap for Lung Cancer
Surgery has long been the gold standard for diagnosis and management of early-stage operable lung cancer. For patients with inoperable disease or more extensive disease, however, alternative approaches are emerging. For example, there are ample data to support stereotactic body radiation therapy as an alternative treatment.1 Percutaneous ablation, however, despite being available for 2 decades, is…
-
Joshua Bauml, MD, moves to The Janssen Pharmaceutical Companies of Johnson & Johnson
Joshua Bauml, MD, has moved to The Janssen Pharmaceutical Companies of Johnson & Johnson from the University of Pennsylvania. Dr. Bauml was with the University of Pennsylvania for a decade—2 years as a fellow and 8 years as faculty—most recently servicing as an Assistant Professor of Medicine. Dr. Bauml will be joining the lung cancer…
-
Jean-Charles Soria, MD, PhD Joins Amgen
Jean-Charles Soria, MD, PhD, joined Amgen in early August 2021 as senior vice president of the oncology therapeutic sector. Prof. Soria, previously served as senior vice president of Research & Development in Oncology at AstraZeneca, where he was responsible for strategy and development of new immuno-oncology, cell therapy, and conjugated antibody agents. Most recently Dr.…
-
Suresh S. Ramalingam, MD, Appointed Executive Director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University
Suresh S. Ramalingam, MD, was appointed as the executive director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University on July 01, 2021. Previously he served as the deputy director of Winship Cancer Institute. Dr. Ramalingam is also the Roberto D. Goizueta distinguished chair for…
-
Economics of Locally Advanced Lung Cancer Before and During COVID-19 Pandemic: A Perspective for Developing Countries
Since December 2019, the world has been mired in a pandemic that has displaced other 21st-century health priorities for many populations. The social significance and speed of contagion from COVID-19 have altered criteria for public health prioritization, to the detriment of other health problems including noncommunicable diseases, which are recognized as the leading cause of…
-
Awareness-raising Bike Ride in The Netherlands Connected Hospitals, Patients
Patients and supporters cycled nearly 1,150 kilometers through The Netherlands on May 21, 2021 in a “White Ribbon Tour” to raise awareness for lung cancer. The grassroots event was organized by Niels Harthoorn, age 22, an industrial engineering and management student at the University of Twente, and a patient with lung cancer. For the ride,…
-
A Balancing Act: Managing Patients’ Expectations
By Leah Lawrence Posted: December 11, 2019 Many patients newly diagnosed with lung cancer have difficulty navigating the world of cancer when unexpectedly and unwillingly thrust into it. In addition to understanding their diagnosis, prognosis, and treatment options, patients are also bombarded with an abundance of information on the internet, direct-to-consumer advertising of new cancer…